MacroGenics reports interim lorigerlimab data and expands gynecologic cancer trial
MacroGenics reported interim Phase 2 LINNET data for lorigerlimab in advanced clear cell gynecologic cancer at the 2026 ESMO Congress on October 26, 2026. Among 16 response-evaluable patients, the confirmed objective response rate was 25%, with four responses, while the disease control rate was 44%; all confirmed responses remained ongoing at the analysis. MacroGenics is enrolling 20 additional patients at 3 mg/kg every three weeks and expects updated results in the first half of 2027.
Why it matters
The trial expansion increases the number of CCGC patients available for evaluating lorigerlimab at the lower dose. MacroGenics expects further clinical data in the first half of 2027, while the drug remains investigational and the interim safety and efficacy results do not establish approval or commercial success.
Key facts
- 1The LINNET study included 41 patients across clear cell gynecologic cancer and platinum-resistant ovarian cancer, with 16 CCGC patients evaluable for response. rttnews.com
- 2Lorigerlimab produced a confirmed objective response rate of 25% and a disease control rate of 44% in the CCGC group. rttnews.com
- 3Median progression-free survival was 2.9 months, and the six-month progression-free survival rate was 33%. rttnews.com
- 4Grade 3 or higher treatment-related adverse events occurred in 49% of patients across both study groups. rttnews.com
- 5MacroGenics plans to enroll 20 additional CCGC patients at 3 mg/kg every three weeks and expects updated data in the first half of 2027. rttnews.com
Open questions
- / report different pre-market MGNX moves, of down 1.33% and down 7.69%, respectively.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.